Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Research & Development (2016 - 2025)

Editas Medicine (EDIT) has disclosed Research & Development for 11 consecutive years, with $19.8 million as the latest value for Q3 2025.

  • Quarterly Research & Development fell 58.49% to $19.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $111.2 million through Sep 2025, down 49.52% year-over-year, with the annual reading at $199.2 million for FY2024, 12.16% up from the prior year.
  • Research & Development for Q3 2025 was $19.8 million at Editas Medicine, up from $16.2 million in the prior quarter.
  • The five-year high for Research & Development was $69.6 million in Q4 2023, with the low at $16.2 million in Q2 2025.
  • Average Research & Development over 5 years is $39.8 million, with a median of $40.5 million recorded in 2023.
  • The sharpest move saw Research & Development surged 82.04% in 2024, then tumbled 70.15% in 2025.
  • Over 5 years, Research & Development stood at $37.6 million in 2021, then surged by 38.46% to $52.0 million in 2022, then skyrocketed by 33.77% to $69.6 million in 2023, then tumbled by 30.11% to $48.6 million in 2024, then crashed by 59.32% to $19.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $19.8 million, $16.2 million, and $26.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.